iRhythm Announces $100 Million Accelerated Share Repurchase Agreement
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
iRhythm Holdings (IRTC) entered into a $100 million accelerated share repurchase agreement with JPMorgan Chase Bank to buy back common stock.
The agreement is part of its existing $200 million authorization. iRhythm will pay $100 million initially and receive approximately 80% of the shares expected to be repurchased. The final share count will depend on the volume-weighted average stock price during the agreement, less a discount and subject to contractual adjustments. The company expects final settlement no later than the first quarter of 2027 and plans to use existing cash and cash equivalents. Approximately $100 million will remain authorized after completion.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.$100 million accelerated share repurchase agreement with JPMorgan commits to buying back common stock. 3.3% of market cap
- Minor point. Forward-looking: it has not happened yet and may not happen.Initial delivery will represent approximately 80% of the total shares expected to be repurchased.
- Minor point. Forward-looking: it has not happened yet and may not happen.Final settlement is expected no later than the first quarter of 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.Remaining repurchase authorization will be approximately $100 million after completion.
Negative
- Moderate point. Forward-looking: it has not happened yet and may not happen.The repurchase requires an initial $100 million payment; iRhythm expects to use existing cash and cash equivalents. 3.3% of market cap
News Explained
iRhythm expects to fund the agreed ASR of
Key Figures
- ASR amount
- $100 million
- Accelerated share repurchase agreement
- Initial share delivery
- approximately 80%
- Of the total shares expected to be repurchased under the ASR
- Repurchase authorization
- $200 million
- Previously announced authorization
- Remaining authorization
- approximately $100 million
- Available following completion of the ASR
- Final settlement
- No later than the first quarter of 2027
- Expected ASR settlement
Previous Buybacks Reports
-
Board authorized up to $200 million in repurchases, now followed by a $100 million ASR.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
volume-weighted average price financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Nov. 17, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (Nasdaq: IRTC), a leading digital health care company with a mission to create trusted solutions that detect, predict, and prevent disease, today announced that it has entered into an accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank, National Association (JPMorgan) for
Under the terms of the ASR, iRhythm will make an initial payment of
The company expects to fund this ASR with existing cash and cash equivalents.
About iRhythm Holdings, Inc.
iRhythm is a leading digital health care company with a mission to create trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm's vision is to deliver better data, better insights, and better health for all. For more information, visit www.irhythmtech.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future actions or operating or financial performance. In particular, these statements include, without limitation, statements regarding the ASR, including the total number of shares to be repurchased under the ASR and the timing of final settlement of the ASR, and the amount, timing, methods and sources of funding of repurchases under the share repurchase program and the structure of such repurchases. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: risks relating to the fact that the ASR and other common stock repurchases may not be conducted in the timeframe or in the manner we expect, or at all; risks relating to the final number of shares repurchased under the ASR, which will depend on the trading price of our common stock during the term of the ASR; intense competition in the markets we compete in; fluctuations in our operating results; future reimbursement and regulatory conditions; financial market conditions; the execution and effect of our business strategy; future business decisions made by us and our competitors; and additional risks described in the section entitled “Risk Factors” and elsewhere in our filings made with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed on November 5, 2026. These forward-looking statements speak only as of the date of this press release and should not be unduly relied upon. We undertake no obligation to update them except as required by law.
Investor Contact
Francis Pruell
investors@irhythmtech.com
Media Contact
Kassandra Perry
mediarelations@irhythmtech.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.